
CHA Biotech’s stem cell therapy triggers menstruation return in phase 1
CHA Biotech has posted phase 1 data on its stem cell therapy for premature ovarian insufficiency (POI), pointing to safety and early signs of ovarian function recovery -- including one patient who resumed menstruation after years of amenorrhea. The Korean …